COMPLETED

A Study to Learn How BIIB141 (Omaveloxolone) is Processed in the Body When Taken as Capsules Compared to Sprinkled on Yogurt in Healthy Adults Aged 18 to 55

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

In this study, researchers will learn more about how BIIB141, also known as omaveloxolone or SKYCLARYS®, is processed in the body when taken in different ways. This drug has been approved, or made available for doctors to prescribe, for people with Friedrich's Ataxia (FA) who are at least 16 years old. Currently, people with FA can take it either as whole capsules or opening the capsules and sprinkling its contents over applesauce. The main goal of this study is to learn if BIIB141 is processed any differently when taken sprinkled over low-fat, non-Greek yogurt compared to whole capsules. This will help researchers learn if yogurt could be another option for people to take BIIB141 with. The main questions researchers want to answer in this study are : • How does the body process BIIB141 when taken as whole capsules compared to being sprinkled over yogurt? Researchers will also learn more about : * How many participants have adverse reactions during the study. An adverse reaction is a health problem that may be caused by the study drug. * If there are any changes in the participants' overall health during the study This study will be done as follows: * Participants will be screened to check if they can join the study. The screening period will be up to 28 days, after which participants will check into their study research center. * Participants will stay at the study research center for about 30 days. * This is a "crossover" study. In this kind of study, all participants receive the same 2 or more study drugs (or ways of taking the drug), but the order in which they receive them depends on the group they are randomly assigned to. * In Group 1, participants will take a single dose of BIIB141 as a capsule, followed by a break of 14 days. Then, the participants will take a single dose of BIIB141 sprinkled over yogurt. * In Group 2, participants will take a single dose of BIIB141 sprinkled over yogurt, followed by a break of 14 days. Then, the participants will take a single dose of BIIB141 as a capsule. * Each participant will be in the study for up to 57 days.

Official Title

A Phase 1, Randomized, Open-label, Single-dose, Crossover, Relative Bioavailability Study of Omaveloxolone Intact Capsules Versus Capsule Contents Sprinkled Over Low-fat, Non-Greek Yogurt in Healthy Adult Subjects

Quick Facts

Study Start:2025-06-11

Study Completion:2025-08-19

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:COMPLETED

Study ID

NCT07019064

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 55 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:Yes

Standard Ages:ADULT

Inclusion Criteria	Exclusion Criteria
* Body Mass Index (BMI) at screening between 18 and 32 kilograms per meter square (kg/m\^2), inclusive * Must be in good health as determined by the Investigator, based on medical history and Screening evaluations	* History of any clinically significant cardiac, endocrine, gastrointestinal, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, or renal disease, or other major disease * History of, or ongoing, malignant disease (with exceptions for completely excised basal cell carcinomas and squamous cell carcinomas cured at least 1 year prior to Day -1) * Systolic blood pressure \> 150 millimeters of mercury (mmHg) or \< 90 mmHg after sitting for 5 minutes * Clinically significant, as determined by the Investigator, 12-lead electrocardiogram (ECG) abnormalities * Corrected QT interval \> 450 milliseconds (ms) for males and \> 460 ms for females * Positive diagnostic tuberculosis test result within 30 days of Enrollment * History of, or positive test result for human immunodeficiency virus (HIV) * History of hepatitis C infection or positive test result for hepatitis C virus antibody (HCV Ab) * Current hepatitis B infection * Any value for alanine aminotransferase, aspartate aminotransferase, bilirubin, or serum creatinine above the upper limit of normal * Platelets below the lower limit of normal * Any clinically significant value out of normal range for total white blood cells * Prior exposure to the study treatment * Use of prescription medication (excluding oral contraceptives and hormone replacement therapy), over-the-counter oral medication that alters hepatic or renal clearance, or nutraceuticals within 28 days prior to Day -1 * Use of other over-the-counter oral medication, vitamins, dietary supplements, or antacids within 14 days prior to Day -1

Inclusion Criteria

Exclusion Criteria

* Body Mass Index (BMI) at screening between 18 and 32 kilograms per meter square (kg/m\^2), inclusive
* Must be in good health as determined by the Investigator, based on medical history and Screening evaluations

* History of any clinically significant cardiac, endocrine, gastrointestinal, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, or renal disease, or other major disease
* History of, or ongoing, malignant disease (with exceptions for completely excised basal cell carcinomas and squamous cell carcinomas cured at least 1 year prior to Day -1)
* Systolic blood pressure \> 150 millimeters of mercury (mmHg) or \< 90 mmHg after sitting for 5 minutes
* Clinically significant, as determined by the Investigator, 12-lead electrocardiogram (ECG) abnormalities
* Corrected QT interval \> 450 milliseconds (ms) for males and \> 460 ms for females
* Positive diagnostic tuberculosis test result within 30 days of Enrollment
* History of, or positive test result for human immunodeficiency virus (HIV)
* History of hepatitis C infection or positive test result for hepatitis C virus antibody (HCV Ab)
* Current hepatitis B infection
* Any value for alanine aminotransferase, aspartate aminotransferase, bilirubin, or serum creatinine above the upper limit of normal
* Platelets below the lower limit of normal
* Any clinically significant value out of normal range for total white blood cells
* Prior exposure to the study treatment
* Use of prescription medication (excluding oral contraceptives and hormone replacement therapy), over-the-counter oral medication that alters hepatic or renal clearance, or nutraceuticals within 28 days prior to Day -1
* Use of other over-the-counter oral medication, vitamins, dietary supplements, or antacids within 14 days prior to Day -1

Contacts and Locations

Principal Investigator

Medical Director

STUDY_DIRECTOR

Biogen

Study Locations (Sites)

Trialmed formerly PPD, Austin Clinic

Austin, Texas, 78744

United States

Collaborators and Investigators

Sponsor: Biogen

Medical Director, STUDY_DIRECTOR, Biogen

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-06-11

Study Completion Date2025-08-19

Study Record Updates

Study Start Date2025-06-11

Study Completion Date2025-08-19

Terms related to this study

Additional Relevant MeSH Terms

Healthy Volunteer